10-Q: Cryo-Cell International Reports First Quarter Results, Focuses on Expansion and Clinical Trials

Cryo-Cell International's first quarter results show a slight increase in revenue and a strategic focus on expanding its facilities and advancing clinical trials.

Summary

• Cryo-Cell International reported a total revenue of $7,852,235 for the three months ended February 29, 2024, a slight increase from $7,824,415 in the same period of 2023.
• Processing and storage fees increased to $7,805,522, up from $7,561,518, driven by a 5% rise in recurring annual storage fee revenue, although new domestic cord blood specimens processed decreased slightly.
• Public cord blood banking revenue decreased significantly to $43,713 from $230,697 in the prior year.
• The company's operating income was $821,223, a decrease from $1,683,171 in the same period last year.
• Net income for the quarter was $556,241, compared to $766,812 in the first quarter of 2023.
• The company is focusing on expanding its facilities, including a new facility in North Carolina, and advancing clinical trials related to its Duke University license agreement.
• The company has a revolving line of credit with a balance of $1,972,728 as of February 29, 2024.
• The company anticipates capital expenditures of approximately $5,000,000 over the next twelve months.
• The company is exploring a potential spin-off of its subsidiary, Celle Corp., which holds assets related to the Duke license agreement.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is growth in the core business, there are also significant decreases in profitability and public banking revenue. The company is making strategic investments, but there are also risks and uncertainties. The sentiment is neutral to slightly negative.

Positives

• Processing and storage fees saw a 3% increase, indicating growth in the core business.
• The company is actively expanding its facilities and pursuing clinical trials, which could lead to future growth.
• The company has a revolving line of credit to support its operations and expansion plans.

Negatives

• Public cord blood banking revenue decreased significantly, impacting overall revenue.
• Operating income and net income decreased compared to the same period last year.
• The company is facing increased selling, general, and administrative expenses.

Risks

• The company faces risks related to the complexities and uncertainties of the potential spin-off of Celle Corp.
• There are risks associated with increased government regulation of stem cell storage facilities.
• The company faces competition from public cord blood banks, particularly in overseas markets.
• There is a risk of decreased demand for umbilical cord blood stem cell storage.
• The company faces risks related to the costs associated with increased growth and the commercial launch of new stem cell types.
• The company faces risks related to technological or medical breakthroughs that could render its business obsolete.
• There are risks related to material failures or malfunctions in storage facilities.
• The company faces risks related to adverse results from litigation matters.
• There are risks related to the success of licensing agreements and their ability to provide royalty fees.
• The company faces risks related to the success of its global expansion initiatives and product diversification.
• There are risks related to the success of clinical trials related to the Duke Agreement.
• The company's internal controls over financial reporting were deemed not effective due to a material weakness.

Future Outlook

The company anticipates making discretionary capital expenditures of approximately $5,000,000 over the next twelve months and intends to transfer assets related to the Duke Agreement into a subsidiary and explore a potential spin-off. The company expects its cash and cash equivalents, marketable securities, and cash flows from future operations, along with external capital, to be sufficient to fund its known cash needs for at least the next 12 months.

Management Comments

• The company is focusing on expanding its facilities and advancing clinical trials related to its Duke University license agreement.
• The company intends to transfer the assets related to the Patent and Technology License Agreement with Duke University and certain other assets into a newly formed, wholly-owned subsidiary to provide more financial flexibility to fund future projects.
• The company also intends to explore spinning off this subsidiary to the Companys shareholders.

Industry Context

The company operates in the competitive stem cell preservation market, facing challenges from both private and public cord blood banks. The company is also expanding into biopharmaceutical manufacturing and operating clinics, which is a growing trend in the industry. The company's focus on clinical trials and new therapies aligns with the industry's push for innovative treatments.

Comparison to Industry Standards

• Cryo-Cell's revenue growth is modest compared to some larger players in the biotech and pharmaceutical sectors, but it is consistent with companies focused on niche markets like cord blood banking.
• The decrease in public cord blood banking revenue is a concern, as this segment is often a source of growth for companies in this space. Companies like CBR (Cord Blood Registry) and ViaCord, which are larger private cord blood banks, have a more diversified revenue stream.
• The company's investment in clinical trials and a new facility is similar to strategies employed by companies like Vericel and Osiris Therapeutics, which are focused on regenerative medicine and cellular therapies.
• The company's reliance on a single technology license agreement with Duke University is a risk, as it makes the company vulnerable to the success of that specific technology. Companies with more diversified portfolios are generally less vulnerable to such risks.
• The company's operating margins are lower than some of the larger pharmaceutical companies, but this is typical for companies in the early stages of clinical development and expansion.

Legal Proceedings

• The company is involved in an arbitration case related to advertising claims, which it intends to contest vigorously.

Stakeholder Impact

• Shareholders may be concerned about the decrease in profitability and public banking revenue.
• Employees may be affected by the company's expansion and potential spin-off.
• Customers may benefit from the company's new services and therapies.
• Suppliers may see increased business opportunities with the company's expansion.

Next Steps

• The company plans to open the Cryo-Cell Institute for Cellular Therapies in fiscal 2024.
• The company intends to transfer assets related to the Duke Agreement into a subsidiary and explore a potential spin-off.
• The company will continue to pursue clinical trials related to the Duke Agreement.
• The company will continue to develop its biopharmaceutical manufacturing capabilities.

Key Dates

Keywords

cord blood, stem cells, cryopreservation, public banking, clinical trials, biopharmaceutical, Duke University, cellular therapies, revenue, storage, PrepaCyte CB, Emmes Biopharma Services